Valuation: Labcorp Holdings Inc.

Market Cap 26.01B 134B 22.68B 21.42B 19.45B 36.44B 2,496B 36.59B 257B 98.99B 1,269B 97.7B 95.54B 4,083B P/E 2026 *
23x
P/E 2027 * 20.6x
Enterprise Value 31.16B 161B 27.17B 25.66B 23.3B 43.65B 2,990B 43.83B 307B 119B 1,520B 117B 114B 4,891B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.97x
Free-Float
99.65%
Yield 2026 *
0.91%
Yield 2027 * 0.92%
1 day-0.94%
Current month+9.66%
1 month+9.66%
3 months+31.82%
6 months+14.62%
Current year+14.62%
1 month 411.09
Extreme 411.09
415.01
Current year 311.86
Extreme 311.86
415.01
1 year 311.86
Extreme 311.86
415.01
3 years 246.75
Extreme 246.75
415.01
5 years 244.57
Extreme 244.57
445.28
10 years 135.25
Extreme 135.25
445.28
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%0.00% - - 26.01B
+0.84%+12.30%+105.38%+623.44% 53.25B
-0.63%+2.94%+15.72%+59.42% 26.01B
-1.94%+1.26%-13.10%-37.94% 6.76B
-2.29%+0.68%-0.76%+171.23% 5.98B
-1.44%-0.63%+15.47%+60.65% 3.3B
-3.67%+18.57%-22.65%+2,433.83% 3.02B
+0.10%+14.95%+130.97%+52.22% 2.56B
+14.45%+1.52%+37.67%+46.04% 2.25B
+3.13%+8.10%-10.08%-54.93% 1.91B
Average +0.76%+5.95%+28.74%+372.66% 11.67B
Weighted average by Cap. +0.00%+8.03%+60.08%+411.12%

Financials

2026 *2027 *
Net sales 14.75B 76.19B 12.86B 12.14B 11.03B 20.66B 1,415B 20.75B 145B 56.14B 720B 55.41B 54.18B 2,315B 15.48B 79.95B 13.5B 12.74B 11.57B 21.68B 1,485B 21.77B 153B 58.91B 755B 58.15B 56.85B 2,430B
Net income 1.13B 5.84B 986M 931M 845M 1.58B 108B 1.59B 11.15B 4.3B 55.15B 4.25B 4.15B 177B 1.24B 6.42B 1.08B 1.02B 929M 1.74B 119B 1.75B 12.25B 4.73B 60.6B 4.67B 4.56B 195B
Net Debt 5.15B 26.6B 4.49B 4.24B 3.85B 7.22B 494B 7.25B 50.8B 19.6B 251B 19.35B 18.92B 808B 4.5B 23.26B 3.93B 3.71B 3.37B 6.31B 432B 6.33B 44.41B 17.14B 220B 16.91B 16.54B 707B
Logo Labcorp Holdings Inc.
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
320.71USD
Average target price
344.25USD
Spread / Average Target
+7.34%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!